Shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) have been assigned a consensus rating of “Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $12.42.
A number of brokerages have recently commented on CLBT. Needham & Company LLC boosted their price objective on Cellebrite DI from $13.00 to $13.50 and gave the stock a “buy” rating in a research report on Thursday, March 28th. Craig Hallum lifted their price objective on shares of Cellebrite DI from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. William Blair raised Cellebrite DI from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 13th. Lake Street Capital began coverage on Cellebrite DI in a report on Friday, April 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Finally, Bank of America upped their price target on Cellebrite DI from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, April 1st.
View Our Latest Analysis on CLBT
Hedge Funds Weigh In On Cellebrite DI
Cellebrite DI Stock Performance
NASDAQ CLBT opened at $11.07 on Thursday. Cellebrite DI has a one year low of $5.22 and a one year high of $12.50. The firm has a 50 day simple moving average of $11.18 and a 200-day simple moving average of $9.53. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -25.74, a PEG ratio of 1.89 and a beta of 1.51.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last posted its quarterly earnings results on Thursday, February 15th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The business had revenue of $93.01 million during the quarter, compared to the consensus estimate of $85.43 million. Cellebrite DI had a negative net margin of 24.94% and a positive return on equity of 173.14%. Equities analysts predict that Cellebrite DI will post 0.32 EPS for the current fiscal year.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
- Five stocks we like better than Cellebrite DI
- Insider Buying Explained: What Investors Need to Know
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- 3 Small Caps With Big Return Potential
- Generac Powers Ahead on the Electrification Mega-Trend
- Using the MarketBeat Dividend Yield Calculator
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.